The HillCenter·
The GLP-1 blind spot: Why the FDA’s new eye stroke warning matters
It forces the medical community to treat these therapies with clinical gravity instead of casual enthusiasm.
Read at The Hill →
It forces the medical community to treat these therapies with clinical gravity instead of casual enthusiasm.

<iframe src="https://statesidedaily.com/embed/cluster/fb932c19879e34a361f6b4f06fcaa07539240a80" width="100%" height="320" style="border:0;max-width:680px" loading="lazy" title="The GLP-1 blind spot: Why the FDA’s new eye stroke warning matters"></iframe>